Psychopathologic syndromes during treatment with gyrase inhibitors;Psychopathologische Syndrome unter Behandlung mit Gyrasehemmern

Nervenarzt

Volumn 68, Issue 1, 1997, Pages 38-47

  Hollweg, M ^a   Kapfhammer, H P ^a   Krupinski, M ^a   Moller H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

adverse drug reactions; fluorquinolones; gyrase inhibitors; risk analysis

Indexed keywords

CIPROFLOXACIN; FLEROXACIN; GYRASE INHIBITOR; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ADVERSE DRUG REACTION; AFFECTIVE NEUROSIS; AGE; AGED; ARTICLE; CLINICAL ARTICLE; DELIRIUM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MALE; ORAL DRUG ADMINISTRATION; PARANOIA; STRESS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 0031044588     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050094     Document Type: Article

References (53)

1. Akaike N, Shirasaki T, Yakushiji T (1991) Quinolones and fenbufen interact with GABAA receptor in dissociated hippocampal cells of rat. J Neurophysiol 66: 497-504
2. Arning M, Wolf HH, Aul C, Heyll A, Scharf RE, Schneider W (1990) Infection prophylaxis in neutropenic patients with acute leukaemia. A randomized, comparative study with ofloxacin. J Antimicrob Chemother [Suppl D] 26: 137-142
3. Arzneimittelkommission der deutschen Ärzteschaft (1987) Neue Risikoinformation zu Ofloxacin (Tarivid®). Dtsch Ärztebl 84: 178-180
4. Arzneimittelkommission der deutschen Ärzteschaft (1995) Suizidalität im Zusammenhang mit der Anwendung von Gyrasehemmern (Fluor-Chinoionen). Dtsch Ärztebl 92: A-1197
5. Ball P (1989) Adverse reactions and interactions of fluorquinolones. Clin Invest Med 12: 28-34
6. Blomer R, Bruch K, Krauss H, Wacheck W (1986) Safety of ofloxacin - adverse drug reactions reported during phase-II studies in Europe and Japan. Infection [Suppl 4] 14: 332-334
7. Bowie WR, Willetts V, Jewesson PJ (1989) Adverse reactions in a dose ranging study with a new long-acting fluorquinolone, fleroxacin. Antimicrob Agents Chemother 33: 1778-1782
8. Brensing KA, Ruddel H, Schmieder RE, Schulte W (1989) Visual and auditory impairment due to therapy with ofioxacin. Med Welt 40: 748-751
9. Davey PG (1988) Overview of drug interactions with the quinolones. J Antimicrob Chemother [Suppl C] 22: 97-107
10. Davies BI, Maesen FP, Teengs JP, Baur C (1986) The quinolones in chronic bronchitis. Pharm Weekbl Sci 8: 53-59
11. Davies BI, Maesen FP (1987) Respiratory infections: clinical experiences with the new quinolones. Pharm Weekbl Sci 9: 53-57
12. Deppermann KM, Lode H (1993) Fluorquinolones: interaction profile during enterai absorption. Drugs [Suppl 3] 45: 65-72
13. Dopff C, Mertes PM, Nace C, Gerard A, Voiriot P, Preiss MA, May T, Canton P, Dureux JB (1990) L'association penicilline G-ofloxacine: une réponse au traitement empirique des pneumopathies communautaires. Pathol Biol (Paris) 38: 526-529
14. Farrington J, Stoudemire A, Tierney J (1995) The role of ciprofloxacin in a patient with delirium due to multiple etiologies. Gen Hosp Psychiatry 17: 47-53
15. Frazer M, Gault R (1986) Death as a resuat of an adverse reaction from nalidixic acid. J Forensic Sci 31: 1145-1149
16. Getenet JC, Croistle B, Vighetto A, Grochowicki M, Goudable B, Trillet M (1993) Idiopathic intracranial hypertension after ofloxacin treatment. Acta Neurol Scand 87: 503-504
17. Gleckman R, Alvarez S, Joubert DW, Matthews SJ (1979) Drug therapy reviews: nalidixic acid. Am J Hosp Pharm 36: 1071-1076
18. Greil W, Hoilweg M (1992) Psychische unerwünschte Arzneimittelwirkungen von internistisch eingesetzten Medikamenten. In: Hippius H, Lauter H, Greil W (Hrsg) Psychiatrie für die Praxis 16-Psychische Störungen bei körperlichen Erkrankungen. MMW, München, S60-71
19. Grohmann R, Bullinger-Naber M, Naber D (1987) Psychische Effekte bei Nicht-Psychopharmaka. Münch Med Wochenschr 129: 603-605
20. Hollweg M, Krupinski M, Soyka M (1995a) Psychische Nebenwirkungen von Nicht-Psychopharmaka. Münch Med Wochenschr 137: 326-330
21. Hollweg M, Soyka M, Greil W (1995b) Mefloquin-induzierte Psychosen - Probleme der Kausalzuordnung anhand zweier kasuistischer Berichte. Psychiatr Prax 22: 33-36
22. Hollweg M, Kapfhammer HP (1997) Paranoide Psychose nach Behandlung mit dem Antibiotikum Ofloxacin. Psychiatr Prax (im Druck)
23. Huber G (1988) Körperlich begründbare psychische Störungen bei Intoxikationen, Altgemein- und Stoffwechselstörungen, bei inneren und dermatologischen Erkrankungen, Endokrinopathien, Generationsvorgängen, Vitaminmangel und Hirntumoren. In: Kisker KP, Lauter H, Meyer JE, Müller C, Strömgren E (Hrsg) Organische Psychosen. Psychiatrie der Gegenwart 6. Springer, Berlin Heidelberg New York, S197-252
24. Jüngst G, Mohr R (1987) Side effects of ofloxacin in clinical trials in postmarketing surveillance. Drugs [Suppl 1] 34: 144-149
25. Jüngst G, Mohr R (1988) Overview of postmarketing experience with ofloxacin in Germany. J Antimicrob Chemother 22:167-175
26. Kapfhammer HP (1992) Psychische Störungen bei körperlichen Erkrankungen: Erfahrungen im psychiatrischen Konsiliardienst. In: Hippius H, Lauter H, Greil W (Hrsg) Psychiatrie für die Praxis 16 - Psychische Störungen bei körperlichen Erkrankungen. MMW, München, S11-30
27. Keller H (1991) Vergleich der Nebenwirkungsprofile verschiedener Substanzen wie Penicilline, Tetrazykline, Sulfonamide und Chinolone. Infection [Suppl 1] 19: 19-24
28. Koppel C, Hopfe T, Menzei J (1990) Central anticholinergic syndrome after ofloxacin overdose and therapeutic doses of diphenhydramine and chlormezanone. J Toxicol Clin Toxicol 28: 249-253
29. Koverech A, Picari M, Granata F, Fostini R, Toniolo D, Recchia G (1986) Safety profile of ofloxacin: the Italian data base. Infection [Suppl 4] 14: 335-337
30. Medical Letter (1993) Drugs that cause psychiatric symptoms. Med Lett Drugs Ther 35: 65-70
31. Meher LK, Tripathy D, Acharya S (1992) Ciprofloxacin induced psychosis. J Assoc Physicians India 40: 418-419
32. Monk JP, Campoli-Richards DM (1987) Ofloxacin: a review of its antibacterial activity, pharmakokinetic properties and therapeutic use. Drugs 33: 346-391
33. Oron JD, Ivorra J, Portilla S, Esteve J (1992) Reaccion psicotica tras la administracion de indometacina y ciprofloxacino. Rev Clin Esp 191: 401
34. Polk RE (1989) Drug-drug interactions with ciprofloxacin and other fluorquinolones. Am J Med 87: 76-81
35. Reeves RR (1992) Ciprofloxacin induced psychosis. Ann Pharmacother 26: 930-931
36. Rietbrock N, Staib AH (1987) Gyrase-Hemmer: unerwünschte zentralnervöse Wirkungen. Dtsch Med Wochenschr 112: 201
37. Salm EF, Egbert AC, Maartense E, Hart W, Stricker BH (1994) Psychotische reacties tijdens het gebruik van chinolonen. Ned Tijdschr Geneeskd 138: 1080-1082
38. Schwabe U, Pfaffrath D (Hrsg) (1993) Arzneiverordnungsreport '93. Fischer, Stuttgart New York, S66-67
39. Shah PM, Mulert R (1990) Safety profile of quinolones. Eur Urol [Suppl 1] 17: 46-51
40. Shirasaki T, Harata N, Nakaye T, Akaike N (1991) Interaction of various antiinflammatories and quinolone antimicrobials on GABA-response in rat dissociated hippocampal pyramidal neurons. Brain Res 562: 329-331
41. Shirasaki T, Harata N, Nakaye T, Akaike N (1991) Quinolones do not interact with NMDA receptor in dissociated rat hippocampal neurons. Brain Res 562: 344-346
42. Simon C, Stille W (1985) Antibiotika-Therapte in Klinik und Praxis. Schattauer, Stuttgart New York, S209-220
43. Stahlmann R, Lode H (1988) Safety overview: toxicity, adverse effects and drug interactions. In: Andriole V (ed) The quinolones. Academic Press, New York London, pp 201-233
44. Stahlmann R (1990) Safety profile of quinolones. J Antimicrob Chemother [Suppl D] 26: 31-44
45. Staib AH, Harder S, Mieke S, Beer C, Stille W, Shah PM, Frech K (1986) Gyrasehemmer können die Coffein-Elimination verzögern. Dtsch Med Wochenschr 111: 1500
46. Stapel A, Freymann H, Ruge W (1990) Die Bedeutung von Ofloxacin für die Behandlung der infektexacerbierten COLD. Pneumologie 44: 289-290
47. Tack KJ, Smith JA (1989) The safety profile of ofloxacin. Am J Med [Suppl 6c] 87: 78-81
48. Taga F, Kobayashi F, Saito S, Ooie T, Kawahara F, Uchida H, Shimada J, Hori S, Sakai O (1990) Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals. Arzneimittelforschung 40: 900-904
49. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M (1987) Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 42: 33-41
50. Unseld E, Ziegler G, Gemeinhardt A, Janssen U Klotz U (1990) Possible interaction of fluorquinolones with the benzodiazepine-GABA A-receptor complex. Br J Clin Pharmacol 30: 63-70
51. Williams PD, Helton DR (1991) The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol Lett 58: 23-28
52. Wolfhagen MJ, Hoepelman AI, Verhoef J (1990) Double-blind dose-range-finding study of fleroxacin (RO 23-6240; AM-883) for treatment of complicated urinary tract infections. Antimicrob Agents Chemother 34: 409-412
53. Zaudig M, Bose M von, Weber MM, Bremer D, Ziegelgänsberger W (1989) Psychotoxic effects of ofloxacin. Pharmacopsychiatry 22: 11-15